Quality of life reporting in kidney cancer clinical trials
Quality-of-life (QoL) is very important to patients when they are [...]
Survival after second-line therapy in patients with metastatic kidney cancer treated with first-line immunotherapy combinations
This study looked at real world information from patients with [...]
Finding cancers missed during the pandemic
As many of you know, the COVID-19 pandemic has delayed [...]
NHS long-term workforce plan
Over 100 health and care organisations, including the Royal College [...]
Cost of living support for people with cancer
Macmillan have regularly updated information on support for people with [...]
Taking action on equalities in rare and less common cancers: Understanding the issues
More than half of all cancer deaths in the UK [...]
Nivolumab plus ipilimumab for advanced kidney cancer after progression on immunotherapy
This phase 2 study looked at the effect on survival [...]
CAR T-cell therapy shows promise in kidney cancer
A recent study looking at a CAR T-cell therapy (called [...]
Side effect management for kidney cancer treatments
At the International Kidney Cancer Symposium (IKCS) in the USA [...]
Treatment of rare subtypes of kidney cancer
At the International Kidney Cancer Symposium (IKCS) in North America [...]
